Clinical Trials Related to Nab-paclitaxel

Related studies linked through entity extraction aliases.

A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

Status: RECRUITING
Phase: PHASE2/PHASE3

A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy

Status: RECRUITING
Phase: PHASE3

A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

Status: RECRUITING
Phase: PHASE2/PHASE3

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

Status: RECRUITING
Phase: PHASE3

A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC

Status: NOT_YET_RECRUITING
Phase: PHASE2

A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer

Status: RECRUITING
Phase: PHASE1

Neoadjuvant Nab-Paclitaxel Plus Oxaliplatin, S-1, and Sintilimab in Early-Onset Resectable Gastric Cancer

Status: NOT_YET_RECRUITING
Phase: PHASE2

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

Status: RECRUITING
Phase: PHASE3

A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

Status: RECRUITING
Phase: PHASE1/PHASE2

Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

Status: RECRUITING
Phase: PHASE3

QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer

Status: RECRUITING
Phase: PHASE2

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

Status: RECRUITING
Phase: PHASE2/PHASE3

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

Status: RECRUITING
Phase: PHASE1

Probiotics in Advanced Urothelial Carcinoma

Status: RECRUITING
Phase: PHASE2

Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer.

Status: RECRUITING
Phase: PHASE3

A Prospective, Multicenter, Multicohort Phase II Study: Evaluating the Efficacy and Safety of Preoperative Neoadjuvant Treatment With a PD-1 Inhibitor in Combination With Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal Squamous Cell Carcinoma

Status: NOT_YET_RECRUITING
Phase: PHASE2

Second-line Immunotherapy for ES-SCLC

Status: RECRUITING
Phase: NA

HIM Typing Guides the Treatment of Advanced First-Line Triple-Negative Breast Cancer

Status: NOT_YET_RECRUITING
Phase: PHASE2

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

Status: RECRUITING
Phase: PHASE3

Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Monoclonal Antibody in Locally Advanced NSCLC

Status: NOT_YET_RECRUITING
Phase: PHASE2